CompletedPhase 2/3

Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

44 participantsStarted 2006-01

Plain-language summary

Prevalence of heart failure (HF) with left ventricular (LV) diastolic dysfunction and preserved ejection fraction (EF) (HFpEF) is increasing. Prognosis worsens with development of pulmonary vasoconstriction and hypertension (PH) and right ventricular (RV) failure. The investigators aimed at modulating pulmonary vascular tone and RV burden in HFpEF due to high blood pressure (HBP), by using the phosphodiesterase-5 (PDE5) inhibitor sildenafil.

Who can participate

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * LVEF \>50% * sinus rhythm and stable clinical condition defined as no changes in therapeutic regimen, or hospitalization in the 6 months preceding recruitment. * pulmonary artery systolic pressure \> 40 mm Hg, Exclusion Criteria: * Patients receiving nitrates * A history of pulmonary disease * Alternative causes of PH other than cardiac-related * Renal failure (creatinine \> 2mg/dL) * Anemia * Pericardial disease * Cardiac amyloidosis

What they're measuring

Pulmonary hemodynamics

Timeframe: 1 year

Trial details

NCT IDNCT01156636

SponsorUniversity of Milan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-09

View on ClinicalTrials.gov More Pulmonary Hypertension trials